Acumen Pharmaceuticals, Inc. (ABOS)Healthcare | Biotechnology | Newton, United States | NasdaqGS
2.92 USD
-0.11
(-3.630%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.92 |
Hot Take ↕ | Aug. 22, 2026, 1:47 a.m. EDT
The immediate outlook is mixed but leans cautiously upward due to a sharp, recent price recovery. After languishing near $1.50 for much of the past year, the stock has rallied nearly 100% in just two weeks, breaking above key moving averages. However, this momentum is fragile; the statistical forecast model shows very low confidence in this move, suggesting the recent surge may be noise rather than a trend reversal. The massive put wall indicates that smart money remains deeply concerned about further deterioration. Long-term, the investment case is severely compromised. The company has lost over 90% of its value over the last four years, with the last two full years seeing double-digit declines. Fundamentals are dire: negative earnings, negative free cash flow, and a return on equity of -120%. Despite a 'strong buy' analyst recommendation and a high target price, these metrics reflect a business that is burning cash without generating returns. The low beta suggests the stock is currently decoupled from broader market moves, which is dangerous for a biotech firm relying on future catalysts. There is no dividend to provide any cushion. Investors are entirely exposed to capital appreciation risks in a company with a deteriorating balance sheet and a history of significant value destruction. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.129330 |
| AutoTheta | 0.132094 |
| AutoETS | 0.136934 |
| AutoARIMA | 0.137698 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 2.99 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.227 |
| Excess Kurtosis | -1.03 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 55.264 |
| Market Cap | 211,166,480 |
| Forward P/E | -2.04 |
| Beta | 0.33 |
| Website | https://acumenpharm.com |
As of Aug. 22, 2026, 1:47 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (818 contracts) compared to negligible call volume. While there is some call activity at the $5 strike, the overwhelming sentiment is hedging against a drop below the $2.50 level.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.2279413 |
| Address1 | 1,210-1220 Washington St. |
| Address2 | Suite 210 |
| All Time High | 26.98 |
| All Time Low | 0.855 |
| Ask | 2.92 |
| Ask Size | 1 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 426,470 |
| Average Daily Volume3 Month | 473,851 |
| Average Volume | 473,851 |
| Average Volume10Days | 426,470 |
| Beta | 0.334 |
| Bid | 2.17 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 0.792 |
| City | Newton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.92 |
| Current Ratio | 2.466 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.02 |
| Day Low | 2.885 |
| Debt To Equity | 55.264 |
| Display Name | Acumen Pharmaceuticals |
| Earnings Call Timestamp End | 1,786,536,000 |
| Earnings Call Timestamp Start | 1,786,536,000 |
| Earnings Timestamp | 1,786,537,800 |
| Earnings Timestamp End | 1,794,400,200 |
| Earnings Timestamp Start | 1,794,400,200 |
| Ebitda | -105,367,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.259 |
| Enterprise Value | 132,615,472 |
| Eps Current Year | -1.5891 |
| Eps Forward | -1.43278 |
| Eps Trailing Twelve Months | -1.57 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.5009 |
| Fifty Day Average Change | 0.41910005 |
| Fifty Day Average Change Percent | 0.16757968 |
| Fifty Two Week Change Percent | 122.79413 |
| Fifty Two Week High | 3.6 |
| Fifty Two Week High Change | -0.6799998 |
| Fifty Two Week High Change Percent | -0.18888885 |
| Fifty Two Week Low | 1.21 |
| Fifty Two Week Low Change | 1.71 |
| Fifty Two Week Low Change Percent | 1.4132231 |
| Fifty Two Week Range | 1.21 - 3.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,625,146,200,000 |
| Float Shares | 37,045,976 |
| Forward Eps | -1.43278 |
| Forward P E | -2.037996 |
| Free Cashflow | -56,503,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 60 |
| Fullday Change | -0.11 |
| Fullday Change Percent | -3.63036 |
| Fullday Price | 2.92 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -86,787,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.067930005 |
| Held Percent Institutions | 0.66579 |
| Implied Shares Outstanding | 72,317,285 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-01 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts. |
| Long Name | Acumen Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 211,166,480 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_8539521 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -105,044,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 219,482,959 |
| Number Of Analyst Opinions | 5 |
| Open | 3.02 |
| Operating Cashflow | -91,788,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 617 344 4190 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 2.92 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 3.03 |
| Price Eps Current Year | -1.8375181 |
| Price Hint | 4 |
| Price To Book | 3.686869 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.379 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.11 |
| Regular Market Change Percent | -3.63036 |
| Regular Market Day High | 3.02 |
| Regular Market Day Low | 2.885 |
| Regular Market Day Range | 2.885 - 3.02 |
| Regular Market Open | 3.02 |
| Regular Market Previous Close | 3.03 |
| Regular Market Price | 2.92 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 305,767 |
| Return On Assets | -0.45769 |
| Return On Equity | -1.20505 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 72,317,285 |
| Shares Percent Shares Out | 0.0446 |
| Shares Short | 3,225,089 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,814,458 |
| Short Name | Acumen Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0639 |
| Short Ratio | 8.9 |
| Source Interval | 15 |
| State | MA |
| Symbol | ABOS |
| Target High Price | 10.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 7.4 |
| Target Median Price | 8.0 |
| Total Cash | 110,197,000 |
| Total Cash Per Share | 1.524 |
| Total Debt | 31,646,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.57 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.4076 |
| Two Hundred Day Average Change | 0.51240015 |
| Two Hundred Day Average Change Percent | 0.21282612 |
| Type Disp | Equity |
| Volume | 305,767 |
| Website | https://acumenpharm.com |
| Zip | 2,465 |